Biogen reports better-than-expected Spinraza sales; FDA to discuss opioid prescriptions with payers; UnitedHealth Group launches media review
Walgreens ends merger with Rite Aid; Biogen hires former Novartis exec as SVP of corporate affairs; FDA takes new measures to drive drug pricing competition
This and other changes in the market have created demand for new offerings, like mobile-friendly sites, video, and patient communities.
WPP creates WPP Health & Wellness; Publicis Health formalizes new name; 10 ways healthcare companies are testing Instagram
Drugmakers are becoming much more cautious with their budgets, WebMD executives said.
Pharma execs raise concerns about Trump's plans for the FDA; Merck ends study of experimental Alzheimer's drug; Amgen seeks new indication for Blincyto
Endo settles pay-for-delay charges; Trump signs order withdrawing U.S. from TPP; administration considers Patrick Soon-Shiong for healthcare role
IBM develops chip to detect early stages of cancer; Theranos plans to develop a "minilab;" Aetna and Humana to sell $117 million in assets
Groups urge disclosure of payments to nurse practitioners and physician assistants; Horizon seeks $3-billion acquisition of Depomed; Sanofi closes $245-million agreement to buy priority-review voucher
FDA advisory panel recommends Amgen's T-Vec; Teva again makes the case for a merger with Mylan; the FDA approves injection to treat double chins
Novo Nordisk's Saxenda to cost $1,000 a month; Boehringer Ingelheim's drug receives priority review; AbbVie's hep.-C treatment Viekira Pak generates $231 million in first-quarter sales
Actavis and Allergan have a $66-billion-dollar deal, Merck's Vytorin hits its endpoint, and Pfizer puts up $850 million for an experimental cancer drug.
Pfizer reportedly not interested in acquiring AZ; high deductible plans set to envelop healthcare insurance exchanges; GSK's mature drug portfolio finds a wholesale suitor.
Valeant's war for Allergan also includes a soft touch when it comes to doctors: the WSJ reports that the company is winning over professionals with trips and consulting offers.
An analyst says the $12.2B deal creates a one-stop shopping experience for hospitals.
Salix-Cosmo tax-inversion deal quashed, chronic heart failure market set to expand, rising generic drug prices get lawmakers' attention, NICE gives leukemia drug a thumbs-down, FDA has a good rep
The Chesterbrook, PA, drug manufacturer announced Monday Endo's unsolicited $2.2-billion bid undervalued the company.
Endo's timing also comes as Auxilium has committed to reorganizing and merging with Canada's QLT.
PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.
Allergan sets a shareholder voting date, Novo describes the types of acquisitions it will consider, and the AstraZeneca-Pfizer talks can now reopen.
Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.
The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.
GlaxoSmithKline, Actelion, Sanofi and Roche are said to be among a host of suitors.
CEO Severin Schwan tells Reuters that the Swiss firm will be looking for small acquisitions and partnerships.
The deal includes a $1.6-billion fee if AbbVie tries to walk away.
Shire and AbbVie's courtship has entered round five. A deal would offer AbbVie tax relief, and possibly make it an acquisition target.
NuPathe decided Teva's $144-million offer was a better fit, ending its possible Endo merger.
Novartis prepares for a strategic review that hints at scuttling lesser-performing businesses; Regeneron's Eylea sales prompt expansion; Pfizer targets diabetes and obesity; and the FDA approves an MS stem cell trial
Perrigo sweeps Elan off its feet for $8.6 billion, and Valeant is slashing 2,700 jobs.
Over the weekend, Publicis Omnicom vaulted past WPP to become the world's biggest ad holding company. The task now falls on its co-CEOs to sort out any conflicts and prevent defections.